A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis

Trial Profile

A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Short ragweed pollen allergen extract (Ragwitek) (Primary) ; Timothy grass pollen allergen extract (Grastek) (Primary)
  • Indications Allergic asthma; Seasonal allergic rhinitis
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrails.gov.
    • 13 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrails.gov.
    • 21 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrails.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top